Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.

Thursday, October 29, 2009 General News
Email Print This Page Comment bookmark
Font : A-A+

NANJING, China, Oct. 29 Simcere Pharmaceutical Group(NYSE: SCR) ("Simcere" or the "Company"), a leading pharmaceutical companyspecializing in the development, manufacturing, and marketing of brandedgeneric and proprietary pharmaceuticals in China, today announced that it hasentered into an agreement to acquire a 74.49% stake in ChinaVax, a CaymanIslands company that, as its sole business, holds a 13.27% stake in JiangsuYanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen"). After thecompletion of this acquisition, and together with a 37.5% stake in JiangsuYanshen acquired in May 2009, Simcere will control a 50.77% stake in JiangsuYanshen.

"China's emerging vaccine industry has shown strong growth potential. Weare delighted to make this additional investment in Jiangsu Yanshen, followingour acquisition of a 37.5% stake earlier this year," commented Mr. JinshengRen, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group."This investment is in line with Simcere's mid-to-long-term strategy anddemonstrates Simcere's continuing progress in China's vaccine industry."

Located in Changzhou, Jiangsu Province, Jiangsu Yanshen is a leadingChina-based developer and manufacturer of vaccines. Jiangsu Yanshen wasawarded a new drug certificate and production license from China's State Foodand Drug Administration (SFDA) on September 18, 2009 for its Influenza A (H1N1)vaccine. Jiangsu Yanshen has subsequently received orders from China'sMinistry of Industry and Information Technology for 6.3 million doses of theInfluenza A (H1N1) vaccine.

Safe Harbor Statement

This press release contains forward-looking statements. These statementsconstitute "forward-looking" statements within the meaning of Section 21E ofthe Securities Exchange Act of 1934, as amended, and as defined in the U.S.Private Securities Litigation Reform Act of 1995. These forward-lookingstatements can be identified by terminology such as "anticipate," "believe,""estimate," "expect," "forecast," "intend," "may," "plan," "project,""predict," "should" and "will" and similar expressions. These forward lookingstatements are based upon management's current views and expectations withrespect to future events and are not a guarantee of future performance.Furthermore, these statements are, by their nature, subject to a number ofrisks and uncertainties that could cause actual performance and results todiffer materially from those discussed in the forward-looking statements as aresult of a number of factors. Further information regarding these and otherrisks is included in Simcere's filings with the U.S. Securities and ExchangeCommission at . Simcere does not undertake any obligationto update any forward-looking statement, except as required under applicablelaw.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leadingpharmaceutical company specializing in the development, manufacturing, andmarketing of branded generic and proprietary pharmaceuticals in China. Inrecent years, Simcere has been focusing its strategy on the development ofinnovative pharmaceuticals and first-to-market generics, and has introduced aninnovative anti-cancer medication Endu, a first-to-market medication Sinofuan,and first-to-market generics such as Bicun and Anxin. Simcere manufacturesand sells anti-infective medication, anti-cancer medication and strokemanagement medication. Simcere concentrates its research and developmentefforts on the treatment of diseases with high incidence and/or mortalityrates and for which there is a clear demand for more effective pharmacotherapysuch as cancer, strokes, orthopaedics and infectious diseases. For moreinformation about Simcere Pharmaceutical Group, please visit .

SOURCE Simcere Pharmaceutical Group

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store